On April 5, 2024 Shasqi, Inc. ("Shasqi"), a biotech company whose mission is to make cancer drugs more effective with click chemistry, reported it will present five posters on the company’s novel tumor-targeted drug activation approach at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting in San Diego, April 5-10, 2024 (Press release, Shasqi, APR 5, 2024, View Source [SID1234641823]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The posters will describe data generated with Shasqi’s CAPAC (Click Activated Protodrugs Against Cancer) approach. CAPAC uses 2022 Nobel Prize winning technology, click chemistry, to selectively activate high doses of cancer drugs directly at the tumor, minimizing toxicity to healthy cells and potentially improving the therapeutic index by dramatically altering the exposure. This approach overcomes many limitations of antibody-drug conjugates (ADCs).
"We are looking forward to sharing new data from the Shasqi pipeline at AACR (Free AACR Whitepaper)," said Shasqi Vice President of Research, Travis Biechele, Ph.D. "It is exciting to see data showing that we can effectively activate cancer drugs at the tumor using antigen-bound activators, resulting in sustained tumor regression."
Shasqi is advancing a pipeline of assets based on validated targets and payloads. The posters presented at the AACR (Free AACR Whitepaper) meeting will show preclinical efficacy and safety data for assets targeting HER2, TROP2, and NECTIN-4, each paired with either an MMAE or exatecan payload.
Presentations
Abstracts are available and can be viewed on the AACR (Free AACR Whitepaper) website.
Monday, April 8 between 9 AM – 12:30 PM PST
Click chemistry enabled selective activation of highly cytotoxic MMAE payload at tumors using TROP2 targeting agent
Lead Author: George Coricor, Ph.D.
Poster Section 28, Poster Board: 13
Wednesday, April 10 between 9 AM – 12:30 PM PST
Tumor targeted activation of an attenuated exatecan protodrug through Click Chemistry demonstrates efficacy in murine tumor studies
Lead Author: Sangeetha Srinivasan, Ph.D.
Poster Section 26, Poster Board: 1
A click chemistry-based HER2 targeting agent activates a decoupled MMAE payload making it highly differentiated in efficacy and safety than ADCs
Lead Author: Sangeetha Srinivasan, Ph.D.
Poster Section 26, Poster Board: 2
Nectin-4 targeted therapy with MMAE protodrug results in anti-tumor efficacy mediated by click chemistry
Lead Author: George Coricor, Ph.D.
Poster Section 26, Poster Board: 3
Improving anti-tumor efficacy by modulating a separate HER2 activator and an MMAE payload and reuniting both through click chemistry
Lead Author: Stefanie Wagner
Poster Section 26, Poster Board: 4